<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="opmd" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">opmd</book-part-id>
      <title-group>
        <title>Oculopharyngeal Muscular Dystrophy</title>
        <alt-title alt-title-type="alt-title">Synonym: OPMD</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Trollet</surname>
            <given-names>Capucine</given-names>
          </name>
          <xref ref-type="aff" rid="opmd.AFF1"/>
          <degrees>PhD</degrees>
          <email>capucine.trollet@upmc.fr</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Gidaro</surname>
            <given-names>Teresa</given-names>
          </name>
          <xref ref-type="aff" rid="opmd.AFF2"/>
          <degrees>MD, PhD</degrees>
          <email>t.gidaro@institut-myologie.org</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Klein</surname>
            <given-names>Pierre</given-names>
          </name>
          <xref ref-type="aff" rid="opmd.AFF3"/>
          <degrees>MSc</degrees>
          <email>Pierre.klein@upmc.fr</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>P&#x000e9;ri&#x000e9;</surname>
            <given-names>Sophie</given-names>
          </name>
          <xref ref-type="aff" rid="opmd.AFF4"/>
          <degrees>MD, PhD</degrees>
          <email>Sophie.perie@tnn.aphp.fr</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Butler-Browne</surname>
            <given-names>Gillian</given-names>
          </name>
          <xref ref-type="aff" rid="opmd.AFF5"/>
          <degrees>PhD</degrees>
          <email>Gillian.butler-browne@upmc.fr</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Lacau St Guily</surname>
            <given-names>Jean</given-names>
          </name>
          <xref ref-type="aff" rid="opmd.AFF6"/>
          <degrees>MD</degrees>
          <email>Jean.lacau@tnn.aphp.fr</email>
        </contrib>
      </contrib-group>
      <aff id="opmd.AFF1">Universit&#x000e9; Pierre et Marie Curie<break/>Institut de Myologie, CNRS<break/>Paris, France</aff>
      <aff id="opmd.AFF2">Universit&#x000e9; Pierre et Marie Curie<break/>Institut de Myologie, CNRS<break/>Paris, France</aff>
      <aff id="opmd.AFF3">Universit&#x000e9; Pierre et Marie Curie<break/>Institut de Myologie, CNRS<break/>Paris, France</aff>
      <aff id="opmd.AFF4">Service d'ORL et Chirurgie Cervico-Faciale de l&#x02019;H&#x000f4;pital Tenon (AP-HP)<break/>Universit&#x000e9; Pierre et Marie Curie<break/>Paris, France</aff>
      <aff id="opmd.AFF5">Universit&#x000e9; Pierre et Marie Curie<break/>Institut de Myologie, CNRS<break/>Paris, France</aff>
      <aff id="opmd.AFF6">Service d'ORL et Chirurgie Cervico-Faciale de l&#x02019;H&#x000f4;pital Tenon (AP-HP)<break/>Universit&#x000e9; Pierre et Marie Curie<break/>Paris, France</aff>
      <pub-history>
        <date iso-8601-date="2001-03-08" date-type="created">
          <day>08</day>
          <month>03</month>
          <year>2001</year>
        </date>
        <date iso-8601-date="2014-02-20" date-type="updated">
          <day>20</day>
          <month>02</month>
          <year>2014</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="oca4" document-type="chapter">Oculocutaneous Albinism Type 4</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="opa" document-type="chapter">Optic Atrophy Type 1</related-object>
      <abstract id="opmd.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Oculopharyngeal muscular dystrophy (OPMD) is characterized by ptosis and swallowing difficulties due to selective involvement of the muscles of the eyelid and pharynx, respectively. The mean age of onset of ptosis is usually 48 years and onset of dysphagia is 50 years. Early symptoms of dysphagia are increased time needed to consume a meal and an acquired avoidance of dry foods. Swallowing difficulties determine prognosis, and increase the risk for potentially life-threatening aspiration pneumonia and poor nutrition. Other signs observed as the disease progresses are tongue weakness (82%), proximal lower-extremity weakness (71%), wet voice due to pooling of saliva (67%), limitation of upward gaze (61%), facial muscle weakness (43%), and proximal upper extremity weakness (38%). Involvement of the nervous system occurs on occasion. Severe OPMD, representing 5% to 10% of all OPMD, is characterized by onset of ptosis and dysphagia before age 45 years and incapacitating proximal leg weakness that starts before age 60 years. Some individuals with severe involvement eventually need a wheelchair. </p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>OPMD is suspected based on clinical criteria; the diagnosis is confirmed by molecular genetic testing of <italic toggle="yes">PABPN1</italic>. Ptosis is defined as vertical separation of at least one palpebral fissure that measures less than 8 mm at rest. Dysphagia is determined by physical examination, a videoendoscopic swallowing study (VESS), videofluoroscopic swallowing study (VFSS), and a swallowing time greater than seven seconds when drinking 80 mL of ice-cold water. Confirmatory diagnosis depends on detection of an expansion of a GCN trinucleotide repeat in the first exon of <italic toggle="yes">PABPN1</italic>. Normal alleles contain ten GCN trinucleotide repeats. Autosomal dominant alleles range in size from 12 to 17 GCN repeats; autosomal recessive alleles comprise 11 GCN repeats. Muscle biopsy is warranted only in individuals with suspected OPMD who have two normal <italic toggle="yes">PABPN1</italic> alleles. </p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment for ptosis may include blepharoplasty by either resection of the levator palpebrea aponeurosis or frontal suspension of the eyelids. The common treatment for dysphagia is cricopharyngeal myotomy. However, despite the high rate of immediate improvement in swallowing with relief of dysphagia, in a very high proportion of patients progressive dysphagia recurs in the next few years.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> To reduce the risk for the most common complications of OPMD (aspiration pneumonia, weight loss, and social withdrawal) the following are recommended: annual flu vaccination for the elderly; prompt evaluation of a productive cough; dietary supplements as needed to maintain weight gain; and when socializing with others, diet restricted to foods that are easily swallowed.</p>
          <p><italic toggle="yes">Surveillance:</italic> The frequency of follow-up neurologic evaluations depends on the degree of ptosis, dysphagia, and muscle weakness; routine ophthalmologic evaluation to monitor degree of ptosis and need for surgical intervention; routine reevaluation for functional signs of dysphagia through videoscopy and fiberoscopy.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>OPMD is inherited in either an autosomal dominant (AD) or an autosomal recessive (AR) manner. </p>
          <p>AD OPMD: The proportion of OPMD caused by <italic toggle="yes">de novo</italic> mutation is unknown, but appears to be small. Each child of an individual with AD OPMD (i.e., who is heterozygous for one expanded allele in the normal range [GCN 12-17]) has a 50% chance of inheriting the expanded allele and being affected. </p>
          <p>AR OPMD: Each sib of an affected individual has 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. The offspring of an individual with AR OPMD are obligate heterozygotes (carriers) for a mutant allele causing OPMD; their risk of being affected is less than 1%. </p>
          <p>AD OPMD and AR OPMD: Prenatal testing for pregnancies at increased risk is technically possible if the expanded <italic toggle="yes">PABPN1</italic> GCN repeat has been identified in an affected family member. However, requests for prenatal testing for adult-onset conditions that do not affect intellect or life span and result in relatively mild physical limitations are not common. </p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="opmd.Diagnosis">
        <title>Diagnosis</title>
        <sec id="opmd.Clinical_Criteria">
          <title>Clinical Criteria</title>
          <p><bold>Autosomal dominant oculopharyngeal muscular dystrophy (OPMD).</bold> The following three criteria are required for a diagnosis of autosomal dominant OPMD: </p>
          <list list-type="bullet">
            <list-item>
              <p>A positive family history with involvement of two or more generations </p>
            </list-item>
            <list-item>
              <p>The presence of ptosis defined as EITHER vertical separation of at least one palpebral fissure that measures less than 8 mm at rest OR previous corrective surgery for ptosis </p>
            </list-item>
            <list-item>
              <p>The presence of dysphagia, defined as a swallowing time greater than seven seconds when drinking 80 mL of ice-cold water [<xref ref-type="bibr" rid="opmd.REF.bouchard.1992.296">Bouchard et al 1992</xref>]. A videoendoscopic swallowing study (VESS) and videofluoroscopic swallowing study (VFSS) are essential to document the dysfunction of the pharyngeal muscles and upper esophageal sphincter (UES) [<xref ref-type="bibr" rid="opmd.REF.dodds.1990.965">Dodds et al 1990</xref>, <xref ref-type="bibr" rid="opmd.REF.langmore.1991.678">Langmore et al 1991</xref>, <xref ref-type="bibr" rid="opmd.REF.stguily.1995.723">St Guily et al 1995</xref>, <xref ref-type="bibr" rid="opmd.REF.perie.1998.1712">P&#x000e9;ri&#x000e9; et al 1998</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Autosomal recessive OPMD</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The symptoms and signs are the same as for autosomal dominant OPMD, but are later in onset (age &#x02265;60 years) than in the autosomal dominant form (see <xref ref-type="sec" rid="opmd.Natural_History">Clinical Description</xref>). </p>
            </list-item>
            <list-item>
              <p>Family history is consistent with autosomal recessive inheritance (i.e., affected sibs, unaffected parents, and/or parental consanguinity). </p>
            </list-item>
          </list>
        </sec>
        <sec id="opmd.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p>Molecular genetic testing of <italic toggle="yes">PABPN1</italic> is used to confirm the diagnosis in individuals known or suspected to have OPMD (see <xref ref-type="fig" rid="opmd.F1">Figure 1</xref>). A pathogenic variant is defined as a larger than normal "GCN" trinucleotide repeat in the first exon of <italic toggle="yes">PABPN1</italic> (previously called <italic toggle="yes">PABP2</italic>) [<xref ref-type="bibr" rid="opmd.REF.brais.1998.164">Brais et al 1998</xref>] (<xref ref-type="table" rid="opmd.T.summary_of_molecular_genetic_test">Table 1</xref>). </p>
          <p>Note: Because four different codons &#x02014; GCA, GCT, GCC, and GCG &#x02014; encode the amino acid alanine, GCN, where N represents any A/C/G/T nucleotide, is a generic designation for these four possible codons. A recent European Neuromuscular Center (ENMC) workshop on OPMD [<xref ref-type="bibr" rid="opmd.REF.raz.2013.516">Raz et al 2013</xref>] suggested the following nomenclature for number of triplet repeats/number of alanine of <italic toggle="yes">PABPN1</italic> variants: </p>
          <list list-type="bullet">
            <list-item>
              <p>Normal allele: (GCN)10 / Ala10</p>
            </list-item>
            <list-item>
              <p>Pathogenic alleles: (GCN)11-17 and Ala11&#x02013;17, where the range of triplet repeats/alanines is 11-17</p>
            </list-item>
          </list>
          <p>When available, the full sequence of normal and pathogenic alleles should be reported; for example, an Ala13 allele may have a sequence of (GCG)10(GCA)(GCG)2. </p>
          <p>The nomenclature of the Human Genome Variation Society for these alleles is summarized in <xref ref-type="sec" rid="opmd.Molecular_Genetics">Molecular Genetics</xref>. </p>
          <p><bold>Normal alleles</bold> have ten GCN repeats (GCN)10 (previously referred to as the (GCG)6 normal allele) encoding ten alanines (Ala10). </p>
          <p>Note: <italic toggle="yes">PABPN1</italic> variants were first described as pure (GCG) expansions of a (GCG)<sub>6</sub> stretch coding for six alanines in the first exon [<xref ref-type="bibr" rid="opmd.REF.brais.1998.164">Brais et al 1998</xref>]. However, approximately 25% of these variants consist of (GCN) repeats [<xref ref-type="bibr" rid="opmd.REF.nakamoto.2002.474">Nakamoto et al 2002</xref>], each encoding alanine. </p>
          <p><bold>Autosomal dominant alleles</bold> have 12 to 17 GCN repeats. In one study [<xref ref-type="bibr" rid="opmd.REF.brais.1998.164">Brais et al 1998</xref>], probands had allele frequencies of </p>
          <list list-type="bullet">
            <list-item>
              <p>5% (GCN)12 /Ala12</p>
            </list-item>
            <list-item>
              <p>40% (GCN)13 /Ala13</p>
            </list-item>
            <list-item>
              <p>26% (GCN)14/Ala14</p>
            </list-item>
            <list-item>
              <p>21% (GCN)15/Ala15</p>
            </list-item>
            <list-item>
              <p>7% (GCN)16/Ala16</p>
            </list-item>
            <list-item>
              <p>1% (GCN)17/Ala17</p>
            </list-item>
          </list>
          <p><bold>Autosomal recessive alleles</bold> have 11 GCN repeats (GCN)11/Ala11 (i.e., previously referred to as (GCN)7). Autosomal recessive inheritance has only been observed in one instance in an individual homozygous for (GCN)11 alleles [<xref ref-type="bibr" rid="opmd.REF.brais.1998.164">Brais et al 1998</xref>]. </p>
          <table-wrap id="opmd.T.summary_of_molecular_genetic_test" position="anchor" orientation="portrait">
            <label>Table 1.</label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Oculopharyngeal Muscular Dystrophy</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <th id="hd_b_opmd.T.summary_of_molecular_genetic_test_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_b_opmd.T.summary_of_molecular_genetic_test_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_b_opmd.T.summary_of_molecular_genetic_test_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Pathogenic Allelic Variant</th>
                  <th id="hd_b_opmd.T.summary_of_molecular_genetic_test_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Allelic Variant Detectable by This Method</th>
                </tr>
                <tr>
                  <td headers="hd_b_opmd.T.summary_of_molecular_genetic_test_1_1_1_1" align="left" valign="middle" rowspan="2" colspan="1">
                    <italic toggle="yes">PABPN1</italic>
                  </td>
                  <td headers="hd_b_opmd.T.summary_of_molecular_genetic_test_1_1_1_2" align="left" valign="middle" rowspan="2" colspan="1">Targeted mutation analysis&#x000a0;<sup>2</sup></td>
                  <td headers="hd_b_opmd.T.summary_of_molecular_genetic_test_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Heterozygosity for (GCN)<sub>12-17</sub>
</td>
                  <td headers="hd_b_opmd.T.summary_of_molecular_genetic_test_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;99%, autosomal dominant&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_b_opmd.T.summary_of_molecular_genetic_test_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Homozygosity for (GCN)<sub>11</sub>
</td>
                  <td headers="hd_b_opmd.T.summary_of_molecular_genetic_test_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">&#x0003e;99%, recessive&#x000a0;<sup>4</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="opmd.TF.1">
                <label>1.</label>
                <p>See <related-object source-id="gene" document-id="opmd" object-id="opmd.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="opmd.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants. </p>
              </fn>
              <fn id="opmd.TF.1.1">
                <label>2.</label>
                <p>Testing to determine the size of the GCN trinucleotide repeat in the first exon of <italic toggle="yes">PABPN1</italic> is more than 99% sensitive and 100% specific.</p>
              </fn>
              <fn id="opmd.TF.1.2">
                <label>3.</label>
                <p>Growing evidence indicates that &#x0003e;99% of individuals with a severe autosomal dominant OPMD-like phenotype have a <italic toggle="yes">PABPN1</italic> (GCN) expansion.</p>
              </fn>
              <fn id="opmd.TF.1.3">
                <label>4.</label>
                <p>One case reported [<xref ref-type="bibr" rid="opmd.REF.brais.1998.164">Brais et al 1998</xref>]</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="opmd.Additional_Testing">
          <title>Additional Testing</title>
          <p><bold>Muscle biopsy.</bold> Previously the diagnosis of OPMD was based on the presence of intranuclear inclusions (INI) on muscle biopsy; currently muscle biopsy is only warranted in individuals who have two normal <italic toggle="yes">PABPN1</italic> alleles. </p>
          <list list-type="bullet">
            <list-item>
              <p>INI, considered a specific histologic hallmark of OPMD, consist of tubular filaments [<xref ref-type="bibr" rid="opmd.REF.tome.1980.85">Tom&#x000e9; &#x00026; Fardeau 1980</xref>] that are up to 250 nm in length and have an external diameter of 8.5 nm and an internal diameter of 3 nm. Of the nuclei seen in every ultra-thin section of deltoid muscle by electron microscopy, 4%-5% contain INI [<xref ref-type="bibr" rid="opmd.REF.tome.1980.85">Tom&#x000e9; &#x00026; Fardeau 1980</xref>]. With use of a different technique (KCl-pretreatment followed by PABPN1 immunostaining), the percentage of INI was recently estimated at between 2% and 15% of myonuclei in OPMD muscles [<xref ref-type="bibr" rid="opmd.REF.gidaro.2013.234">Gidaro et al 2013</xref>]. </p>
            </list-item>
            <list-item>
              <p>To date, OPMD INI differ from other types of intranuclear inclusions described in other muscle disorders [<xref ref-type="bibr" rid="opmd.REF.tome.1980.85">Tom&#x000e9; &#x00026; Fardeau 1980</xref>], such as the 15-18 nm filaments described in the nucleus and cytoplasm in individuals with sporadic inclusion body myositis (IBM) [<xref ref-type="bibr" rid="opmd.REF.coquet.1990.393">Coquet et al 1990</xref>]. </p>
            </list-item>
          </list>
          <p>Besides the INI, all biopsies from clinically affected or unaffected OPMD muscles show dystrophic changes: variation in the diameter of muscle fibers, atrophic angulated muscle fibers, ragged red fibers, and rimmed vacuoles [<xref ref-type="bibr" rid="opmd.REF.tome.1994.1">Tom&#x000e9; &#x00026; Fardeau 1994</xref>, <xref ref-type="bibr" rid="opmd.REF.gidaro.2013.234">Gidaro et al 2013</xref>]. Note that although the presence of rimmed vacuoles may be useful for diagnosis of OPMD, they are not present in all OPMD muscle biopsies [<xref ref-type="bibr" rid="opmd.REF.fukuhara.1980.229">Fukuhara et al 1980</xref>]; nor are rimmed vacuoles specific for OPMD: they have been consistently found in several other muscular diseases; for example, in IBM [<xref ref-type="bibr" rid="opmd.REF.askanas.1995.486">Askanas &#x00026; Engel 1995</xref>], where they are much more numerous than in OPMD [<xref ref-type="bibr" rid="opmd.REF.leclerc.1993.283">Leclerc et al 1993</xref>].</p>
          <p><bold>Electromyography (EMG)</bold> of weak muscles usually reveals discrete signs of a myopathic process [<xref ref-type="bibr" rid="opmd.REF.bouchard.1997.S22">Bouchard et al 1997</xref>]. Very mild neuropathic findings have been reported, but are thought to be related in most cases to old age or concomitant disease. EMG is not necessary for OPMD diagnosis because it is clinically nonspecific.</p>
          <p><bold>Serum CK</bold> concentrations elevated two to seven times above the normal value have been reported in individuals with OPMD with severe leg weakness [<xref ref-type="bibr" rid="opmd.REF.barbeau.1996.1">Barbeau 1996</xref>]. In most cases, however, serum CK concentration is normal or up to twice the upper normal value. CK level is not relevant for the diagnosis or follow up of persons with OPMD.</p>
        </sec>
      </sec>
      <sec id="opmd.Clinical_Description">
        <title>Clinical Characteristics</title>
        <sec id="opmd.Natural_History">
          <title>Clinical Description</title>
          <p>Oculopharyngeal muscular dystrophy (OPMD) is characterized by late-onset involvement of small distinct muscles of the eyelid (levator palpebrae superioris muscle) causing ptosis and of the pharynx causing dysphagia. Ptosis and dysphagia usually become manifest around the fifth decade. Disease progression is slow.</p>
          <p>Ptosis is always bilateral, but may be asymmetric, at least in the early stage of disease [<xref ref-type="bibr" rid="opmd.REF.brais.2003.252">Brais 2003</xref>]. Individuals with severe bilateral ptosis may compensate for visual field limitation with &#x0201c;astrologist&#x02019;s posture,&#x0201d; retroflexion of the neck and downward gaze combined with contraction of the frontalis muscles [<xref ref-type="bibr" rid="opmd.REF.ruegg.2005.574">Ruegg et al 2005</xref>]. </p>
          <p>Dysphagia is detected first for solid foods, later also for liquids. The degenerative dystrophy and progressive onset of fibrosis in the pharyngeal muscles create difficulties in propulsing the food bolus in the pharynx. This together with a decreased relaxation of the cricopharyngeal muscle (the main muscle of the upper esophageal sphincter (UES) located between the pharynx and the esophagus) result in a delay in the transfer of the bolus through the UES.</p>
          <p>Of note, while in the past dysphagia resulted in poor nutrition that usually caused death by starvation, recent progress (especially in the treatment of pharyngeal dysfunction) has improved the quality of life for persons with OPMD.</p>
          <p>Extraocular muscles may become gradually affected but complete external ophthalmoplegia is rare [<xref ref-type="bibr" rid="opmd.REF.tome.1994.1">Tom&#x000e9; &#x00026; Fardeau 1994</xref>]. </p>
          <p>Weakness and atrophy can occur in limb girdle muscles (shoulder girdle muscles more than pelvic girdle muscles). Limb muscle involvement is symmetric and non-selective. </p>
          <p>Distal muscle weakness has been described in a Japanese family [<xref ref-type="bibr" rid="opmd.REF.goto.1977.600">Goto et al 1977</xref>, <xref ref-type="bibr" rid="opmd.REF.satoyoshi.1977.89">Satoyoshi &#x00026; Kinoshita 1977</xref>] and in other ethnic groups [<xref ref-type="bibr" rid="opmd.REF.jaspar.1977.272">Jaspar et al 1977</xref>, <xref ref-type="bibr" rid="opmd.REF.scrimgeour.1984.763">Scrimgeour &#x00026; Mastaglia 1984</xref>]; however, distal muscle involvement has not been associated with typical OPMD [<xref ref-type="bibr" rid="opmd.REF.schotland.1964.433">Schotland &#x00026; Rowland 1964</xref>, <xref ref-type="bibr" rid="opmd.REF.vita.1983.57">Vita et al 1983</xref>]. </p>
          <p>Although OPMD is considered a primary muscle disorder, in rare instances peripheral nervous system involvement has been described. The first of such reported cases presented a severe depletion of myelinated fibers in endomysial nerve twigs of extraocular, pharyngeal, and lingual muscles pointing to neurogenic changes in these muscles and suggesting nerve involvement [<xref ref-type="bibr" rid="opmd.REF.probst.1982.209">Probst et al 1982</xref>, <xref ref-type="bibr" rid="opmd.REF.schober.2001.45">Schober et al 2001</xref>]. Other cases have also shown central nervous system involvement [<xref ref-type="bibr" rid="opmd.REF.linoli.1991.325">Linoli et al 1991</xref>]. <xref ref-type="bibr" rid="opmd.REF.dubbioso.2012.833">Dubbioso et al [2012]</xref> described an individual with central nervous system involvement with impaired executive functions.</p>
          <p><bold>Autosomal dominant OPMD.</bold> The age of onset of autosomal dominant OPMD varies and is often difficult to pinpoint. In a study of 72 symptomatic individuals of French-Canadian ancestry with a (GCN)13 pathogenic variant, the mean age of onset for ptosis was 48.1 years (range 26-65 years) and for dysphagia, 50.7 years (range 40-63 years). </p>
          <p>Early symptoms suggestive of dysphagia caused by OPMD are increased time needed to consume a meal and an acquired avoidance of dry foods. Other signs observed as the disease progresses are tongue atrophy and weakness (82%), proximal lower-extremity weakness (71%), wet voice due to pooling of saliva (67%), limitation of upward gaze (61%), facial muscle weakness (43%), and proximal upper-extremity weakness (38%) [<xref ref-type="bibr" rid="opmd.REF.bouchard.1997.S22">Bouchard et al 1997</xref>]. </p>
          <p>Disease severity varies. Severe disease, representing 5% to 10% of all OPMD, is characterized by onset of ptosis and dysphagia before age 45 years; incapacitating proximal leg weakness starts before age 60 years. Some eventually need a wheelchair. </p>
          <p>Although OPMD does not appear to reduce life span, quality of life in later years is greatly diminished [<xref ref-type="bibr" rid="opmd.REF.becher.2001.2437">Becher et al 2001</xref>]. Of note, the severity of dysphagia determines the prognosis, as it leads to potentially life-threatening aspiration pneumonia and poor nutrition.</p>
          <p><bold>Autosomal recessive OPMD.</bold> Ptosis and dysphagia occur after age 60 years. Some evidence suggests that heterozygous carriers of the recessive (GCG)7 allele may be at higher risk of developing dysphagia after age 70 years. </p>
        </sec>
        <sec id="opmd.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The variability of age of onset and severity of weakness may depend on the number of (GCN) repeats; this important issue is as yet unresolved. </p>
          <p><bold>Severe autosomal dominant OPMD.</bold> Of the 5% to 10% of all individuals with autosomal dominant OPMD who have severe disease: </p>
          <list list-type="bullet">
            <list-item>
              <p>20% are compound heterozygotes for an autosomal dominant pathogenic allele in the (GCN)12-17 range and an autosomal recessive allele of (GCN)11 [<xref ref-type="bibr" rid="opmd.REF.brais.1998.164">Brais et al 1998</xref>]. While (GCN)11 homozygosity is known to lead to autosomal recessive OMPD, in this scenario it acts as a severity modifier of a dominant OMPD phenotype, presumably because more mutant proteins are produced. The (GCN)11 carrier frequency is 1% to 2% of North American, European, and Japanese populations. </p>
            </list-item>
            <list-item>
              <p>In 80% the reason for the increased disease severity is unknown. Of note, severely affected individuals cluster in families, a phenomenon suggesting that other genetic factors modulate severity. </p>
            </list-item>
          </list>
          <p><bold>Homozygous autosomal dominant OPMD.</bold> The most severe OPMD presentation is reported in individuals who are homozygous for an autosomal dominant OPMD pathogenic variant [<xref ref-type="bibr" rid="opmd.REF.blumen.1996.1324">Blumen et al 1996</xref>, <xref ref-type="bibr" rid="opmd.REF.brais.1998.164">Brais et al 1998</xref>, <xref ref-type="bibr" rid="opmd.REF.blumen.1999.115">Blumen et al 1999</xref>]. A study of four French-Canadian and three Bukhara Jewish OPMD homozygotes documented that on average the onset was 18 years earlier than in (GCN)13 heterozygotes. </p>
          <p><bold>Autosomal recessive OPMD</bold> (i.e., caused by homozygosity for (GCN)11 alleles) has a later onset and milder disease than autosomal dominant OPMD. </p>
        </sec>
        <sec id="opmd.Penetrance">
          <title>Penetrance</title>
          <p>Decade-specific cumulative penetrance for individuals with an autosomal dominant (GCN)13 pathogenic variant [<xref ref-type="bibr" rid="opmd.REF.brais.1997.S70">Brais et al 1997</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Age &#x0003c;40 years: 1% </p>
            </list-item>
            <list-item>
              <p>Age 40-49 years: 6% </p>
            </list-item>
            <list-item>
              <p>Age 50-59 years: 31% </p>
            </list-item>
            <list-item>
              <p>Age 60-69 years: 63% </p>
            </list-item>
            <list-item>
              <p>Age &#x0003e;69 years: 99% </p>
            </list-item>
          </list>
          <p>Thus, autosomal dominant OPMD resulting from (GCN)13 heterozygosity is fully penetrant after age 70 years.</p>
        </sec>
        <sec id="opmd.Anticipation">
          <title>Anticipation</title>
          <p>The GCN/alanine triplet repeat in <italic toggle="yes">PABPN1</italic> is mitotically and meiotically stable. Therefore, expansion of the triplet repeat in meiosis is rare. Clinical anticipation is not observed with this disease. The estimated secondary mutation of an existent dominant pathogenic variant is on the order of 1:500 meioses [<xref ref-type="bibr" rid="opmd.REF.brais.1998.164">Brais et al 1998</xref>]. </p>
        </sec>
        <sec id="opmd.Prevalence">
          <title>Prevalence</title>
          <p><bold>Autosomal dominant.</bold> The prevalence of OPMD has been estimated to be 1:100,000 in France, 1:1000 in the French-Canadian population of the province of Quebec, and 1:600 among Bukhara Jews living in Israel [<xref ref-type="bibr" rid="opmd.REF.brais.1995.429">Brais et al 1995</xref>, <xref ref-type="bibr" rid="opmd.REF.blumen.1997.S38">Blumen et al 1997</xref>, <xref ref-type="bibr" rid="opmd.REF.brunet.1997.S34">Brunet et al 1997</xref>]. In the United States, the majority of affected individuals are of French-Canadian extraction, though a large number are also of other backgrounds, including Jewish Ashkenazi [<xref ref-type="bibr" rid="opmd.REF.victor.1962.1267">Victor et al 1962</xref>] and Spanish American in Texas [<xref ref-type="bibr" rid="opmd.REF.becher.2001.2437">Becher et al 2001</xref>] and California [<xref ref-type="bibr" rid="opmd.REF.grewal.1999.1378">Grewal et al 1999</xref>]. </p>
          <p>Autosomal dominant OPMD has been identified in individuals from more than 30 countries.</p>
          <p><bold>Autosomal recessive.</bold> The predicted prevalence of the autosomal recessive form should be in the order of 1:10,000 in France, Quebec, and Japan based on the carrier frequency of the (GCN)11 autosomal recessive mutation in these populations [<xref ref-type="bibr" rid="opmd.REF.brais.1998.164">Brais et al 1998</xref>]. </p>
        </sec>
      </sec>
      <sec id="opmd.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">PABPN1</italic>. </p>
      </sec>
      <sec id="opmd.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis should include all late-onset neuromuscular diseases characterized by swallowing difficulties and/or ptosis (see <xref ref-type="fig" rid="opmd.F1">Figure 1</xref>):</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="myotonic-d" document-type="chapter"><bold>Myotonic dystrophy type 1</bold></related-object> (caused by an expansion of the CTG trinucleotide repeat in <italic toggle="yes">DMPK</italic> and inherited in an autosomal dominant manner)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="myotonic-d2" document-type="chapter"><bold>Myotonic muscular dystrophy type 2</bold></related-object> (caused by a CCTG tetranucleotide repeat expansion in intron 1 of <italic toggle="yes">CNBP</italic> and inherited in an autosomal dominant manner)</p>
          </list-item>
          <list-item>
            <p>Autosomal dominant distal myopathy </p>
            <list list-type="bullet">
              <list-item>
                <p>Distal hereditary motor neuropathy type VII (HMN7A; Harper-Young myopathy) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/158580">158580</ext-link>), caused by mutation of <italic toggle="yes">SLC5A7</italic>. In these families spinal muscular atrophy is accompanied by vocal cord and pharyngeal weakness without ptosis [<xref ref-type="bibr" rid="opmd.REF.young.1980.413">Young &#x00026; Harper 1980</xref>]. </p>
              </list-item>
              <list-item>
                <p><xref ref-type="bibr" rid="opmd.REF.feit.1998.1732">Feit et al [1998]</xref> described a distal myopathy with a similar phenotype of vocal cord and pharyngeal dysfunction (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/606070">606070</ext-link>), caused by mutation of <italic toggle="yes">MATR3</italic>. </p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter"><bold>Mitochondrial myopathy</bold></related-object> with or without progressive external ophthalmoplegia (PEO) including <related-object link-type="booklink" source-id="gene" document-id="mngie" document-type="chapter">mitochondrial neurogastrointestinal encephalomyopathy disease</related-object> (MNGIE syndrome) </p>
          </list-item>
          <list-item>
            <p>Myasthenia gravis (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/254200">254200</ext-link>). The absence of family history and the fluctuation of symptoms in myasthenia gravis usually distinguish the two conditions. If in doubt, electromyography and neostigmine testing can confirm the diagnosis of myasthenia gravis, and molecular genetic testing can confirm the diagnosis of OPMD. </p>
          </list-item>
          <list-item>
            <p>Inclusion body myositis, polymyositis, and progressive bulbar palsy. These conditions do not have ptosis. </p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="bpes" document-type="chapter"><bold>Blepharophimosis, ptosis, and epicanthus inversus</bold></related-object>
<bold>(BPES).</bold> In this condition, the ptosis is usually congenital, it is always associated with epicanthus inversus, and dysphagia is not a feature. </p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="cfeom" document-type="chapter"><bold>Congenital fibrosis of the extraocular muscles</bold></related-object>
<bold>(CFEOM).</bold> In this condition, the ptosis is congenital and dysphagia is not a feature. </p>
          </list-item>
          <list-item>
            <p>Other. At least one other dominant OPMD-like condition, which is more severe and is not caused by GCN expansion in <italic toggle="yes">PABPN1</italic>, appears to exist [<xref ref-type="bibr" rid="opmd.REF.hill.2004.CD004303">Hill et al 2004</xref>]. </p>
          </list-item>
        </list>
        <p><bold>Oculopharyngodistal myopathy</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/164310">164310</ext-link>) is still a poorly characterized condition in which dysphagia, ptosis, and distal weakness appear earlier in the twenties than in OPMD. The mode of transmission is still unclear; both dominant and recessive modes have been proposed. Pathologically, no intranuclear inclusions are observed and no <italic toggle="yes">PABPN1</italic> (GCN) pathogenic variants are observed [<xref ref-type="bibr" rid="opmd.REF.vandersluijs.2004.1499">van der Sluijs et al 2004</xref>].</p>
      </sec>
      <sec id="opmd.Management">
        <title>Management</title>
        <sec id="opmd.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and the needs of an individual diagnosed with oculopharyngeal muscular dystrophy (OPMD), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Evaluation for swallowing difficulties by history and in more severe cases with a videoendoscopic swallowing study (VESS) and/or videofluoroscopic swallowing study (VFSS) [<xref ref-type="bibr" rid="opmd.REF.dodds.1990.965">Dodds et al 1990</xref>, <xref ref-type="bibr" rid="opmd.REF.langmore.1991.678">Langmore et al 1991</xref>, <xref ref-type="bibr" rid="opmd.REF.stguily.1995.723">St Guily et al 1995</xref>, <xref ref-type="bibr" rid="opmd.REF.perie.1998.1712">P&#x000e9;ri&#x000e9; et al 1998</xref>]. </p>
              <list list-type="bullet">
                <list-item>
                  <p>VESS gives indirect signs of upper esophageal sphincter (UES) dysfunction </p>
                </list-item>
                <list-item>
                  <p>VFSS gives a direct evaluation of the UES using radiopaque barite in the tracheobronchial tree </p>
                </list-item>
                <list-item>
                  <p>The drink test, a global quantitative functional evaluation of swallowing, is abnormal when it takes longer than seven seconds to drink 80 mL of ice-cold water [<xref ref-type="bibr" rid="opmd.REF.bouchard.1992.296">Bouchard et al 1992</xref>, <xref ref-type="bibr" rid="opmd.REF.brais.1995.429">Brais et al 1995</xref>]. Questionnaires can also be used to evaluate the degree of dysphagia (i.e., the Mc Horney score [<xref ref-type="bibr" rid="opmd.REF.mchorney.2002.97">McHorney et al 2002</xref>] and the Salassa grade [<xref ref-type="bibr" rid="opmd.REF.salassa.1999.230">Salassa 1999</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Neuromuscular examination performed by a neurologist to determine overall disease progression and the presence (and severity) of ptosis, dysphagia, proximal weakness, and the presence or absence of any other neurologic findings</p>
            </list-item>
            <list-item>
              <p>Consideration of muscle biopsy in those cases with more severe or complicated presentations</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="opmd.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>
            <bold>Ptosis</bold>
          </p>
          <p>Surgery is recommended when ptosis interferes with vision or appears to cause cervical pain secondary to constant dorsiflexion of the neck. The two types of blepharoplasty used to correct the ptosis are resection of the levator palpebrae aponeurosis and frontal suspension of the eyelids [<xref ref-type="bibr" rid="opmd.REF.codere.1993.1">Codere 1993</xref>]. </p>
          <list list-type="bullet">
            <list-item>
              <p>Resection of the aponeurosis is easily done, but usually needs to be repeated once or twice [<xref ref-type="bibr" rid="opmd.REF.rodrigue.1997.S82">Rodrigue &#x00026; Molgat 1997</xref>]. </p>
            </list-item>
            <list-item>
              <p>Frontal suspension of the eyelids uses a thread of muscle fascia as a sling; the fascia is inserted through the tarsal plate of the upper eyelid and the ends are attached in the frontalis muscle, which is relatively preserved in OPMD [<xref ref-type="bibr" rid="opmd.REF.codere.1993.1">Codere 1993</xref>]. The major advantage of frontal suspension of the eyelids is that it is permanent; however, the procedure requires general anesthesia. </p>
            </list-item>
          </list>
          <p>
            <bold>Dysphagia</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Food should be cut into small pieces. </p>
            </list-item>
            <list-item>
              <p>Although no controlled trials have been performed [<xref ref-type="bibr" rid="opmd.REF.hill.2004.CD004303">Hill et al 2004</xref>], surgical intervention for dysphagia should be considered when symptomatic dysphagia is accompanied by marked weight loss, near-fatal choking, and/or recurrent pneumonia [<xref ref-type="bibr" rid="opmd.REF.duranceau.1983.825">Duranceau et al 1983</xref>, <xref ref-type="bibr" rid="opmd.REF.stguily.1995.723">St Guily et al 1995</xref>, <xref ref-type="bibr" rid="opmd.REF.perie.1997.S96">P&#x000e9;ri&#x000e9; et al 1997</xref>, <xref ref-type="bibr" rid="opmd.REF.coiffier.2006.218">Coiffier et al 2006</xref>]. </p>
            </list-item>
            <list-item>
              <p>Cricopharyngeal myotomy, consisting of extramucosal section of the cricopharyngeal muscle that improves swallowing through the upper esophageal sphincter [<xref ref-type="bibr" rid="opmd.REF.montgomery.1971.986">Montgomery &#x00026; Lynch 1971</xref>, <xref ref-type="bibr" rid="opmd.REF.duranceau.1980.33">Duranceau et al 1980</xref>, <xref ref-type="bibr" rid="opmd.REF.stguily.1994.34">St Guily et al 1994</xref>, <xref ref-type="bibr" rid="opmd.REF.stguily.1995.723">St Guily et al 1995</xref>, <xref ref-type="bibr" rid="opmd.REF.duranceau.1997.S85">Duranceau 1997</xref>], is easily performed and immediately improves symptoms in most cases [<xref ref-type="bibr" rid="opmd.REF.duranceau.1983.825">Duranceau et al 1983</xref>]; however, in a very high proportion of patients progressive dysphagia recurs within years [<xref ref-type="bibr" rid="opmd.REF.coiffier.2006.218">Coiffier et al 2006</xref>]. </p>
            </list-item>
          </list>
        </sec>
        <sec id="opmd.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>The major complications of OPMD are aspiration pneumonia, weight loss, and social withdrawal because of frequent choking while eating. To reduce the risk for these complications:</p>
          <list list-type="bullet">
            <list-item>
              <p>Annual flu vaccination is recommended for elderly affected individuals </p>
            </list-item>
            <list-item>
              <p>Consultation should be sought promptly for a productive cough because of the increased risk for lung abscesses. </p>
            </list-item>
            <list-item>
              <p>Dietary supplements should be added if weight loss is significant. </p>
            </list-item>
            <list-item>
              <p>When eating in social settings, affected individuals should either avoid eating or choose foods that are easy to swallow. </p>
            </list-item>
          </list>
          <p>General anesthesia is not contraindicated even though individuals with OPMD may respond differently to certain anesthetics [<xref ref-type="bibr" rid="opmd.REF.caron.2005.393">Caron et al 2005</xref>].</p>
        </sec>
        <sec id="opmd.Surveillance">
          <title>Surveillance</title>
          <p>The frequency of follow-up neurologic evaluations depends on the degree of ptosis, dysphagia, and muscle weakness.</p>
          <p>Perform routine ophthalmologic evaluation o determine if ptosis interferes with driving or is associated with neck pain, and or if the eyelids cover more than 50% of the pupil, findings that might lead to consideration of surgical intervention.</p>
          <p>Perform routine reevaluation for functional signs of dysphagia using videoscopy and fiberoscopy.</p>
        </sec>
        <sec id="opmd.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="opmd.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="opmd.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Repetitive dilatations of the upper-esophageal sphincter with bougies [<xref ref-type="bibr" rid="opmd.REF.mathieu.1997.S100">Mathieu et al 1997</xref>, <xref ref-type="bibr" rid="opmd.REF.manjaly.2012.216">Manjaly et al 2012</xref>] and botulinum toxin injection of the cricopharyngeal muscle [<xref ref-type="bibr" rid="opmd.REF.restivo.2000.1416">Restivo et al 2000</xref>] have been suggested as treatment for dysphagia. </p>
          <p>An autologous cell transplantation clinical phase I/IIa study (ClinicalTrials.gov <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00773227?term=NCT00773227&#x00026;rank=1">NCT00773227</ext-link>) has also been recently described [<xref ref-type="bibr" rid="opmd.REF.perie.2014.219">P&#x000e9;ri&#x000e9; et al 2014</xref>]. The trial was based on the observation that cells isolated from unaffected muscles of persons with OPMD are able to proliferate and differentiate normally, whereas cells isolated from affected muscles have reduced myogenicity (ability to proliferate and differentiate normally) [<xref ref-type="bibr" rid="opmd.REF.perie.2006.770">P&#x000e9;ri&#x000e9; et al 2006</xref>]. The therapeutic strategy is to isolate muscle progenitors (myoblasts) from clinically unaffected muscles of persons with OPMD and implant them into dystrophic pharyngeal muscles to reinforce their motor ability and restore contractility and, thus, reduce the dysphagia. The conclusions of this trial on 12 patients with OPMD support the hypothesis that an injection of autologous myoblasts into pharyngeal muscles is a safe and efficient procedure [<xref ref-type="bibr" rid="opmd.REF.perie.2014.219">P&#x000e9;ri&#x000e9; et al 2014</xref>].</p>
          <p>In cellular models of OPMD, investigators have reduced cellular toxicity by inducing heat shock protein expression using ZnSO4, 8-hydroxyquinoline, ibuprofen, and indomethacin [<xref ref-type="bibr" rid="opmd.REF.wang.2005.3673">Wang et al 2005</xref>] or exposing cells to an anti-PABPN1 single-domain antibody called intrabody that interferes with oligomerization [<xref ref-type="bibr" rid="opmd.REF.verheesen.2006.105">Verheesen et al 2006</xref>]. These intrabodies also reduced intranuclear inclusion (INI) formation and symptoms related to OPMD in a drosophila OPMD model [<xref ref-type="bibr" rid="opmd.REF.chartier.2009.1849">Chartier et al 2009</xref>].</p>
          <p>More recently, investigators have tested molecules that interfere with the Wnt/beta-catenin pathway such as lithium chloride [<xref ref-type="bibr" rid="opmd.REF.abubaker.2013.e821">Abu-Baker et al 2013</xref>].</p>
          <p>In a transgenic mouse model of OPMD, investigators have reduced inclusion formation and cell death with agents that interfere with protein aggregation such as doxycycline [<xref ref-type="bibr" rid="opmd.REF.davies.2005.672">Davies et al 2005</xref>] and trehalose [<xref ref-type="bibr" rid="opmd.REF.davies.2006.23">Davies et al 2006</xref>].These studies suggest that therapeutic trials in OPMD are possible given that some of the tested molecules have already been given to humans. </p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="opmd.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="opmd.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Oculopharyngeal muscular dystrophy is inherited in either an autosomal dominant or an autosomal recessive manner. </p>
        </sec>
        <sec id="opmd.Risk_to_Family_Members__Autosomal_1">
          <title>Risk to Family Members &#x02014; Autosomal Dominant OPMD</title>
          <p><bold>Parents of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with OPMD have an affected parent. Note: In rare instances of a homozygous proband, both parents will be affected (see <bold>Offspring of a proband</bold>, <bold>Homozygotes</bold>)</p>
            </list-item>
            <list-item>
              <p>A proband with OPMD may have the disorder as the result of <italic toggle="yes">de novo</italic> mutation. The proportion of cases caused by <italic toggle="yes">de novo</italic> mutation is unknown but appears to be small. </p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> mutation include clinical evaluation and/or molecular genetic testing. </p>
            </list-item>
          </list>
          <p>Note: Although most individuals diagnosed with OPMD have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</p>
          <p><bold>Sibs of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the status of the parents. </p>
            </list-item>
            <list-item>
              <p>If a parent of the proband has an expanded (GCN) allele, the risk to the sibs of inheriting the expanded allele is 50%. </p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Heterozygotes.</bold> Each child of an individual heterozygous for one expanded allele (GCN)12-17 has a 50% chance of inheriting the expanded allele. </p>
            </list-item>
            <list-item>
              <p><bold>Homozygotes.</bold> A few individuals (French-Canadians and members of the inbred population of Bukhara Jews living in Israel [<xref ref-type="bibr" rid="opmd.REF.blumen.1999.115">Blumen et al 1999</xref>]) who are homozygous for the expanded alleles (GCN)13 have been described. All offspring of such an individual are heterozygous for the expanded allele. </p>
            </list-item>
          </list>
          <p><bold>Other family members of the proband.</bold> The risk to other family members depends on the genetic status of the proband's parents. If a parent is affected, the proband's family members are at risk. </p>
        </sec>
        <sec id="opmd.Risk_to_Family_Members__Autosomal_2">
          <title>Risk to Family Members &#x02014; Autosomal Recessive OPMD</title>
          <p>One individual homozygous for the (GCN)11 allele has been reported [<xref ref-type="bibr" rid="opmd.REF.brais.1998.164">Brais et al 1998</xref>]. This individual has been referred to as having autosomal recessive OPMD. Because the (GCN)11 allele has a 1% to 2% prevalence, other persons who are homozygous for this allele with a mild OPMD phenotype may be unrecognized because of a negative family history. </p>
          <p><bold>Parents of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes and therefore carry one expanded allele. </p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are usually asymptomatic. </p>
            </list-item>
            <list-item>
              <p>Parents of individuals with autosomal recessive OPMD are unlikely to be alive at the time of diagnosis of their child and should not have been affected. </p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. </p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the chance of his/her being a carrier is 2/3. </p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are usually asymptomatic. </p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with autosomal recessive OPMD are obligate heterozygotes (carriers) for an expanded allele causing autosomal recessive OPMD. The risk of the child being affected is less than 1%. </p>
          <p><bold>Other family members of a proband.</bold> Sibs of the proband's parents are at 50% risk of also being carriers. </p>
        </sec>
        <sec id="opmd.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing is possible once the diagnosis has been established in the proband by molecular genetic testing. See <xref ref-type="sec" rid="opmd.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>.</p>
        </sec>
        <sec id="opmd.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Specific risk issues.</bold> Individuals inheriting an autosomal dominant expanded allele from an affected parent and an autosomal recessive expanded allele [(GCN)11] from the other parent will develop a severe form of OPMD (see <xref ref-type="sec" rid="opmd.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>). </p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy. </p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>Testing of at-risk asymptomatic adults</bold> for OPMD is possible using the techniques described in <xref ref-type="sec" rid="opmd.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>. Such testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. When testing at-risk individuals for OPMD, an affected family member should be tested first to confirm the molecular diagnosis in the family. </p>
          <p><bold>Molecular genetic testing of asymptomatic individuals younger than age 18 years</bold> who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</p>
          <p>Genetic testing is indicated in affected or symptomatic individuals in a family with established OPMD regardless of age. </p>
          <p>For more information, see also the National Society of Genetic Counselors <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">position statement</ext-link> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">policy statement</ext-link>: ethical and policy issues in genetic testing and screening of children.</p>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="opmd.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the pathogenic allele(s) have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing for this disease/gene or custom prenatal testing. </p>
          <p>Requests for prenatal testing for adult-onset conditions which (like OPMD) do not affect intellect or life span, result in relatively mild physical limitations, and require that the asymptomatic at-risk parent be tested to confirm the at-risk status of the fetus are very uncommon. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate. </p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the pathogenic allele(s) have been identified. </p>
        </sec>
      </sec>
      <sec id="opmd.Resources">
        <title>Resources</title>
      </sec>
      <sec id="opmd.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">PABPN1</italic> has seven exons. The role of the two long introns preserved in many of its mRNAs is unknown. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="opmd" object-id="opmd.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold> Normal <italic toggle="yes">PABPN1</italic> alleles have (GCN)10 encoding Ala10 residues.</p>
        <p>Note on nomenclature: This <italic toggle="yes">GeneReview</italic> follows the nomenclature recommended by the European Neuromuscular Center (ENMC) workshop on OPMD [<xref ref-type="bibr" rid="opmd.REF.raz.2013.516">Raz et al 2013</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hgvs.org/">Human Genome Variation Society</ext-link>]. </p>
        <p><bold>Pathogenic allelic variants.</bold> See <xref ref-type="sec" rid="opmd.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>. The OPMD pathogenic alleles have an expanded (GCN) sequence that immediately follows the start codon ATG. As in other disorders caused by (CAG)/polyglutamine expansion, it is the absolute size of the domain that is the size of the mutation and not the size of the added expansions. It is not known for certain if the mutation mechanism is expansion of the GCN repeat through slippage or insertion of additional (GCN)s through unequal recombination or gene conversion events [<xref ref-type="bibr" rid="opmd.REF.chen.2005.125">Chen et al 2005</xref>].</p>
        <p><bold>Normal gene product.</bold> PABPN1 protein has at least the following six domains: polyalanine, coil-coiled, RNA binding, two oligomerization, and a nuclear localization signal (NLS) [<xref ref-type="bibr" rid="opmd.REF.calado.2000.2321">Calado et al 2000</xref>, <xref ref-type="bibr" rid="opmd.REF.fan.2001.2341">Fan et al 2001</xref>, <xref ref-type="bibr" rid="opmd.REF.kuhn.2003.16916">Kuhn et al 2003</xref>]. PABPN1 is an abundant nuclear protein of ~49 kd that binds with high affinity to nascent poly(A) tails at the 3' end of mRNAs [<xref ref-type="bibr" rid="opmd.REF.wahle.1993.2937">Wahle et al 1993</xref>, <xref ref-type="bibr" rid="opmd.REF.nemeth.1995.4034">Nemeth et al 1995</xref>]. The poly(A) tail is post-transcriptionally added to the mRNA by a number of <italic toggle="yes">trans</italic>-acting factors including PABPN1, the cleavage and polyadenylation specificity factor (CPSF), and the poly(A) polymerase (PAP) [<xref ref-type="bibr" rid="opmd.REF.wahle.1999.277">Wahle &#x00026; Ruegsegger 1999</xref>, <xref ref-type="bibr" rid="opmd.REF.zhao.1999.405">Zhao et al 1999</xref>]. </p>
        <p>It was demonstrated that PABPN1 shuttles between nucleus and cytoplasm [<xref ref-type="bibr" rid="opmd.REF.calado.2000.2321">Calado et al 2000</xref>] and plays a direct role in the export of poly(A) RNA from the nucleus [Apponi et al 2009]. PABPN1 is associated with RNA polymerase II during transcription and accompanies the released transcript though the nuclear pore [<xref ref-type="bibr" rid="opmd.REF.bear.2003.332">Bear et al 2003</xref>, <xref ref-type="bibr" rid="opmd.REF.kerwitz.2003.3705">Kerwitz et al 2003</xref>]. Nuclear export of PABPN1 is temperature sensitive, and depends on RNA binding and ongoing transcription. Nuclear import of PABPN1 is an active transportin-mediated process [<xref ref-type="bibr" rid="opmd.REF.calado.2000.2321">Calado et al 2000</xref>]. </p>
        <p>Several PABPN1 binding partners have been identified to date, including the heterogeneous family members HNRPA/B, HNRPA1 [<xref ref-type="bibr" rid="opmd.REF.fan.2003.244">Fan et al 2003</xref>] and HNRPC [<xref ref-type="bibr" rid="opmd.REF.calapez.2002.795">Calapez et al 2002</xref>]. By immunoprecipitation, PABPN1 was found to interact with proteins of the cap-binding complex (CBP80, CBP20, and EIF4G) and with proteins involved in mRNA decay (Upf2 and Upf3) [<xref ref-type="bibr" rid="opmd.REF.ishigaki.2001.607">Ishigaki et al 2001</xref>]. PABPN1-interacting partners also include HSP40 (DNAJ) and BRG1 [<xref ref-type="bibr" rid="opmd.REF.kim.2001.1129">Kim et al 2001</xref>]. Finally, PABPN1 has been shown to interact with SKIP and to stimulate muscle-specific gene expression when overexpressed [<xref ref-type="bibr" rid="opmd.REF.kim.2001.1129">Kim et al 2001</xref>].</p>
        <p>PABPN1 is also implicated in deadenylation via the CCR4-NOT complex that regulates translation of some transcripts [<xref ref-type="bibr" rid="opmd.REF.chartier.2006.2253">Chartier et al 2006</xref>]. </p>
        <p>Recently, using the A17.1 OPMD mouse model where mutated PABPN1 is overexpressed [<xref ref-type="bibr" rid="opmd.REF.deklerk.2012.9089">de Klerk et al 2012</xref>] or RNAi to deplete PABPN1 in mammalian cells [<xref ref-type="bibr" rid="opmd.REF.jenal.2012.538">Jenal et al 2012</xref>, <xref ref-type="bibr" rid="opmd.REF.beaulieu.2012.e1003078">Beaulieu et al 2012</xref>, <xref ref-type="bibr" rid="opmd.REF.bresson.2013.e1003893">Bresson &#x00026; Conrad 2013</xref>], the following new functions of PABPN1 have been uncovered: </p>
        <list list-type="bullet">
          <list-item>
            <p>Involvement in the choice of alternative polyadenylation sites [<xref ref-type="bibr" rid="opmd.REF.deklerk.2012.9089">de Klerk et al 2012</xref>, <xref ref-type="bibr" rid="opmd.REF.jenal.2012.538">Jenal et al 2012</xref>]. It has been suggested that PABPN1 binds and masks proximal weak polyadenylation sites, competing with the recruitment of CPSF and enhancing the use of distal canonic polyadenylation sites. Such a shift in the cleavage/polyadenylation site is critical for regulation of gene expression (length of 3&#x02019;UTR, miRNA target sites).</p>
          </list-item>
          <list-item>
            <p>Control of lncRNA (long non-coding RNA) expression [<xref ref-type="bibr" rid="opmd.REF.beaulieu.2012.e1003078">Beaulieu et al 2012</xref>]. An RNAseq approach revealed stabilization of a proportion of lncRNA (16%) in cells depleted for PABPN1. This is a polyadenylation-dependent mechanism with PABPN1-sensitive lncRNAs targeted by the exosome and a RNA helicase.</p>
          </list-item>
          <list-item>
            <p>mRNA decay [<xref ref-type="bibr" rid="opmd.REF.bresson.2013.e1003893">Bresson &#x00026; Conrad 2013</xref>]. More precisely, the investigators revealed a new function for PABPN1 in a polyadenylation-dependent pathway of RNA decay that targets export-deficient mRNAs. Lastly, it has been suggested that PABPN1-dependent promotion of PAP activity can stimulate nuclear RNA decay.</p>
          </list-item>
        </list>
        <p><bold>Abnormal gene product.</bold> Various hypotheses of a polyalanine toxicity gain-of-function pathogenic mechanism have been proposed [<xref ref-type="bibr" rid="opmd.REF.brais.1998.164">Brais et al 1998</xref>, <xref ref-type="bibr" rid="opmd.REF.brais.1999.59">Brais et al 1999</xref>, <xref ref-type="bibr" rid="opmd.REF.banerjee.2013.4230">Banerjee et al 2013</xref>]. Abnormal aggregation and inefficient protein degradation are some of the gain-of-function pathogenic mechanisms proposed [<xref ref-type="bibr" rid="opmd.REF.brais.2003.252">Brais 2003</xref>]. In these models, PABPN1 is thought to have a pathogenic expanded polyalanine domain with physical characteristics that cause it to accumulate and interfere with normal cellular processes. However, despite the growing number of studies exploring OPMD pathogenesis, the nature of the underlying pathologic mechanism has yet to be established. More generally, there are suggestions that in addition to having a gain-of-function toxic effect, OPMD aggregates could sequester RNA and proteins including PABPN1 essential for proper cellular function. </p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Accumulation/aggregation.</bold> It was proposed that when more than ten alanines (the normal number) are present in PABPN1, the polyalanine domains polymerize to form stable &#x003b2;-sheets that are resistant to nuclear proteosomal degradation. The polyalanine macromolecules grow over time to form the OPMD PABPN1-containing intranuclear filaments that are seen using electron microscopy [<xref ref-type="bibr" rid="opmd.REF.tome.1980.85">Tom&#x000e9; &#x00026; Fardeau 1980</xref>, <xref ref-type="bibr" rid="opmd.REF.tome.1997.S63">Tom&#x000e9; et al 1997</xref>, <xref ref-type="bibr" rid="opmd.REF.calado.2000.2321">Calado et al 2000</xref>, <xref ref-type="bibr" rid="opmd.REF.gidaro.2013.234">Gidaro et al 2013</xref>]. Various fusion proteins with long polyalanine domains accumulate as intranuclear inclusions (INI) [<xref ref-type="bibr" rid="opmd.REF.gaspar.2000.1957">Gaspar et al 2000</xref>, <xref ref-type="bibr" rid="opmd.REF.rankin.2000.15">Rankin et al 2000</xref>]. In one transfection experiment, a long 37-Ala-GFP fusion protein caused nuclear inclusion formation and cell death [<xref ref-type="bibr" rid="opmd.REF.rankin.2000.15">Rankin et al 2000</xref>].Studies with agents that influence this aggregation have been explored and in most cases improve outcome in cellular and mice models of OPMD [<xref ref-type="bibr" rid="opmd.REF.davies.2005.672">Davies et al 2005</xref>, <xref ref-type="bibr" rid="opmd.REF.wang.2005.3673">Wang et al 2005</xref>, <xref ref-type="bibr" rid="opmd.REF.davies.2006.23">Davies et al 2006</xref>, <xref ref-type="bibr" rid="opmd.REF.verheesen.2006.105">Verheesen et al 2006</xref>].These PABPN1 aggregates are a pathologic hallmark of the disease; however, their exact role in the pathology is still debated. The fact that nuclear aggregates are found in less than 20% of myofiber nuclei in affected and non-affected muscle sections of persons with OPMD [<xref ref-type="bibr" rid="opmd.REF.tome.1980.85">Tom&#x000e9; &#x00026; Fardeau 1980</xref>, <xref ref-type="bibr" rid="opmd.REF.tome.1997.S63">Tom&#x000e9; et al 1997</xref>, <xref ref-type="bibr" rid="opmd.REF.calado.2000.2321">Calado et al 2000</xref>, <xref ref-type="bibr" rid="opmd.REF.gidaro.2013.234">Gidaro et al 2013</xref>] and that both wildtype and expanded PABPN1 proteins can form these aggregates suggest that the presence of PABPN1 aggregates per se may not be sufficient. </p>
          </list-item>
          <list-item>
            <p>
              <bold>Inefficient protein degradation</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Evidence suggesting that polyalanine oligomers form resistant macromolecules in vivo and in vitro includes the following: </p>
                <list list-type="bullet">
                  <list-item>
                    <p>Polyalanine oligomers are known to be resistant to protease digestion or chemical degradation [<xref ref-type="bibr" rid="opmd.REF.forood.1995.7">Forood et al 1995</xref>]. </p>
                  </list-item>
                  <list-item>
                    <p>Polyalanine oligomers form a &#x003b2;-sheet structure in vitro [<xref ref-type="bibr" rid="opmd.REF.forood.1995.7">Forood et al 1995</xref>]. </p>
                  </list-item>
                  <list-item>
                    <p>Polyalanine oligomers containing more than eight alanines in a row form fibrils spontaneously [<xref ref-type="bibr" rid="opmd.REF.blondelle.1997.8393">Blondelle et al 1997</xref>]. PABPN1 molecules in the intranuclear inclusions (INI) of OPMD muscle are more resistant to salt extraction than the protein dispersed in the nucleoplasm [<xref ref-type="bibr" rid="opmd.REF.calado.2000.2321">Calado et al 2000</xref>].</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>In addition, a recent cross-species transcriptomic study using drosophila, mouse, and human samples identified deregulation of the ubiquitin-proteasome system (UPS) as the predominant molecular defect in OPMD [<xref ref-type="bibr" rid="opmd.REF.anvar.2011.15">Anvar et al 2011</xref>].</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>Messenger RNA trapping</bold> is another proposed pathophysiologic hypothesis [<xref ref-type="bibr" rid="opmd.REF.galvao.2001.191">Galvao et al 2001</xref>]. It has been shown that to aggregate and cause toxicity, PABPN1 has to enter the nuclei [<xref ref-type="bibr" rid="opmd.REF.abubaker.2005.766">Abu-Baker et al 2005</xref>]. Inclusion formation and PABPN1 inclusions have broad and significant impact on the expression of numerous genes, in particular ones that are involved in mRNA processing [<xref ref-type="bibr" rid="opmd.REF.corbeilgirard.2005.551">Corbeil-Girard et al 2005</xref>]. </p>
          </list-item>
        </list>
      </sec>
      <sec id="opmd.References">
        <title>References</title>
        <sec id="opmd.Published_GuidelinesConsensus_State">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="opmd.Published_GuidelinesConsensus_State.reflist0">
            <ref id="opmd.REF.americansocietyofhumange.1995.1">
              <mixed-citation publication-type="book">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">online</ext-link>. 2013. Accessed 2-18-15.</mixed-citation>
            </ref>
            <ref id="opmd.REF.MISSING_AUTHOR.1995.1">
              <mixed-citation publication-type="book">Association fran&#x000e7;aise contre les myopathies. Dystrophie Musculaire Oculopharyng&#x000e9;e. Evry, France: Monographies Myoline. 1995.</mixed-citation>
            </ref>
            <ref id="opmd.REF.nationalsocietyofgenetic.2012.1">
              <mixed-citation publication-type="book">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">online</ext-link>. 2012. Accessed 9-26-14. </mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="opmd.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="opmd.Literature_Cited.reflist0">
            <ref id="opmd.REF.abubaker.2005.766">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abu-Baker</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laganiere</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fan</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laganiere</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.</article-title>
                <source>Traffic.</source>
                <year>2005</year>
                <volume>6</volume>
                <fpage>766</fpage>
                <lpage>79</lpage>
                <pub-id pub-id-type="pmid">16101680</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.abubaker.2013.e821">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abu-Baker</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laganiere</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudet</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rochefort</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dion</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/&#x003b2;-catenin pathway.</article-title>
                <source>Cell Death Dis.</source>
                <year>2013</year>
                <volume>4</volume>
                <fpage>e821</fpage>
                <pub-id pub-id-type="pmid">24091664</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.anvar.2011.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Anvar</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>'t Hoen</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venema</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Sluijs</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Engelen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snoeck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trollet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dickson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chartier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonelig</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Ommen</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Maarel</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raz</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients.</article-title>
                <source>Skelet Muscle.</source>
                <year>2011</year>
                <volume>1</volume>
                <fpage>15</fpage>
                <pub-id pub-id-type="pmid">21798095</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.askanas.1995.486">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Askanas</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engel</surname>
                    <given-names>WK</given-names>
                  </name>
                </person-group>
                <article-title>New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies.</article-title>
                <source>Curr Opin Rheumatol.</source>
                <year>1995</year>
                <volume>7</volume>
                <fpage>486</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">8579968</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.banerjee.2013.4230">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Banerjee</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Apponi</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavlath</surname>
                    <given-names>GK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corbett</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <article-title>PABPN1: molecular function and muscle disease.</article-title>
                <source>FEBS J.</source>
                <year>2013</year>
                <volume>280</volume>
                <fpage>4230</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">23601051</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.barbeau.1996.1">
              <mixed-citation publication-type="confproc">Barbeau A. The syndrome of hereditary late-onset ptosis and dysphagia in French Canada. In: Kuhn E, ed. Symposium &#x000fc;ber Progressive Muskeldystrophie. Berlin, Germany: Springer-Verlag; 1996:102-9.</mixed-citation>
            </ref>
            <ref id="opmd.REF.bear.2003.332">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bear</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fomproix</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soop</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bjorkroth</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masich</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daneholt</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Nuclear poly(A)-binding protein PABPN1 is associated with RNA polymerase II during transcription and accompanies the released transcript to the nuclear pore.</article-title>
                <source>Exp Cell Res</source>
                <year>2003</year>
                <volume>286</volume>
                <fpage>332</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">12749861</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.beaulieu.2012.e1003078">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beaulieu</surname>
                    <given-names>YB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleinman</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landry-Voyer</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majewski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bachand</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1.</article-title>
                <source>PLoS Genet.</source>
                <year>2012</year>
                <volume>8</volume>
                <fpage>e1003078</fpage>
                <pub-id pub-id-type="pmid">23166521</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.becher.2001.2437">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Becher</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrison</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maki</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bicknell</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reinert</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartolo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bear</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngeal muscular dystrophy in Hispanic New Mexicans.</article-title>
                <source>JAMA</source>
                <year>2001</year>
                <volume>286</volume>
                <fpage>2437</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">11712939</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.blondelle.1997.8393">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blondelle</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forood</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houghten</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perez-Paya</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Polyalanine-based peptides as models for self-associated beta-pleated-sheet complexes.</article-title>
                <source>Biochemistry</source>
                <year>1997</year>
                <volume>36</volume>
                <fpage>8393</fpage>
                <lpage>400</lpage>
                <pub-id pub-id-type="pmid">9204887</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.blumen.1999.115">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blumen</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korczyn</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Medinsky</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asherov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nisipeanu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Codere</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tome</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease.</article-title>
                <source>Ann Neurol</source>
                <year>1999</year>
                <volume>46</volume>
                <fpage>115</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10401788</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.blumen.1997.S38">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blumen</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nisipeanu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sadeh</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asherov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blumen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wirguin</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khilkevich</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carasso</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korczyn</surname>
                    <given-names>AD</given-names>
                  </name>
                </person-group>
                <article-title>Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel.</article-title>
                <source>Neuromuscul Disord</source>
                <year>1997</year>
                <volume>7</volume>
                <fpage>S38</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">9392014</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.blumen.1996.1324">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blumen</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sadeh</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korczyn</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouche</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nisipeanu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asherov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tome</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <article-title>Intranuclear inclusions in oculopharyngeal muscular dystrophy among Bukhara Jews.</article-title>
                <source>Neurology</source>
                <year>1996</year>
                <volume>46</volume>
                <fpage>1324</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">8628475</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.bouchard.1997.S22">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gould</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>Recent studies on oculopharyngeal muscular dystrophy in Quebec.</article-title>
                <source>Neuromuscul Disord</source>
                <year>1997</year>
                <volume>7</volume>
                <fpage>S22</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9392011</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.bouchard.1992.296">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcoux</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gosselin</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pineault</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>A simple test for the detection of the dysphagia in members of families with oculopharyngeal muscular dystrophy (OPMD).</article-title>
                <source>Can J Neurol Sci</source>
                <year>1992</year>
                <volume>19</volume>
                <fpage>296</fpage>
                <lpage>7</lpage>
              </element-citation>
            </ref>
            <ref id="opmd.REF.brais.2003.252">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngeal muscular dystrophy: a late-onset polyalanine disease.</article-title>
                <source>Cytogenet Genome Res</source>
                <year>2003</year>
                <volume>100</volume>
                <fpage>252</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">14526187</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.brais.1998.164">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xie</surname>
                    <given-names>YG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rochefort</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chretien</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tome</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lafreniere</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rommens</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uyama</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nohira</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blumen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korczyn</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heutink</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathieu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duranceau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Codere</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korcyn</surname>
                    <given-names>AD</given-names>
                  </name>
                </person-group>
                <article-title>Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy.</article-title>
                <source>Nat Genet</source>
                <year>1998</year>
                <volume>18</volume>
                <fpage>164</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9462747</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.brais.1997.S70">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gosselin</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xie</surname>
                    <given-names>YG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tome</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>Using the full power of linkage analysis in 11 French Canadian families to fine map the oculopharyngeal muscular dystrophy gene.</article-title>
                <source>Neuromuscul Disord</source>
                <year>1997</year>
                <volume>7</volume>
                <fpage>S70</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">9392020</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.brais.1999.59">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tome</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngeal muscular dystrophy.</article-title>
                <source>Semin Neurol</source>
                <year>1999</year>
                <volume>19</volume>
                <fpage>59</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">10711989</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.brais.1995.429">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xie</surname>
                    <given-names>YG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weissenbach</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korczyn</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blumen</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tom&#x000e9;</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13.</article-title>
                <source>Hum Mol Genet.</source>
                <year>1995</year>
                <volume>4</volume>
                <fpage>429</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">7795598</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.bresson.2013.e1003893">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bresson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conrad</surname>
                    <given-names>NK</given-names>
                  </name>
                </person-group>
                <article-title>The human nuclear poly(a)-binding protein promotes RNA hyperadenylation and decay.</article-title>
                <source>PLoS Genet.</source>
                <year>2013</year>
                <volume>9</volume>
                <fpage>e1003893</fpage>
                <pub-id pub-id-type="pmid">24146636</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.brunet.1997.S34">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brunet</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tome</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Genealogical study of oculopharyngeal muscular dystrophy in France.</article-title>
                <source>Neuromuscul Disord</source>
                <year>1997</year>
                <volume>7</volume>
                <fpage>S34</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9392013</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.calado.2000.2321">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Calado</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tome</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuhn</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wahle</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carmo-Fonseca</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA.</article-title>
                <source>Hum Mol Genet</source>
                <year>2000</year>
                <volume>9</volume>
                <fpage>2321</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11001936</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.calapez.2002.795">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Calapez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pereira</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calado</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braga</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rino</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carvalho</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tavanez</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wahle</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosa</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carmo-Fonseca</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>The intranuclear mobility of messenger RNA binding proteins is ATP dependent and temperature sensitive.</article-title>
                <source>J Cell Biol</source>
                <year>2002</year>
                <volume>159</volume>
                <fpage>795</fpage>
                <lpage>805</lpage>
                <pub-id pub-id-type="pmid">12473688</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.caron.2005.393">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girard</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girard</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boudreault</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nassif</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chouinard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duranceau</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Cisatracurium pharmacodynamics in patients with oculopharyngeal muscular dystrophy.</article-title>
                <source>Anesth Analg</source>
                <year>2005</year>
                <volume>100</volume>
                <fpage>393</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15673864</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.chartier.2006.2253">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chartier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benoit</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonelig</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.</article-title>
                <source>EMBO J.</source>
                <year>2006</year>
                <volume>25</volume>
                <fpage>2253</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">16642034</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.chartier.2009.1849">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chartier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raz</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sterrenburg</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verrips</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Maarel</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonelig</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2009</year>
                <volume>18</volume>
                <fpage>1849</fpage>
                <lpage>59</lpage>
                <pub-id pub-id-type="pmid">19258344</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.chen.2005.125">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chuzhanova</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stenson</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferec</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>DN</given-names>
                  </name>
                </person-group>
                <article-title>Complex gene rearrangements caused by serial replication slippage.</article-title>
                <source>Hum Mutat</source>
                <year>2005</year>
                <volume>26</volume>
                <fpage>125</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">15977178</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.codere.1993.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Codere</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngeal muscular dystrophy.</article-title>
                <source>Can J Ophthalmol</source>
                <year>1993</year>
                <volume>28</volume>
                <fpage>1</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">8439856</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.coiffier.2006.218">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coiffier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;ri&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lafor&#x000ea;t</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St Guily</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>Long-term results of cricopharyngeal myotomy in oculopharyngeal muscular dystrophy.</article-title>
                <source>Otolaryngol Head Neck Surg.</source>
                <year>2006</year>
                <volume>135</volume>
                <fpage>218</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">16890071</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.coquet.1990.393">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coquet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vital</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Julien</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>Presence of inclusion body myositis-like filaments in oculopharyngeal muscular dystrophy. Ultrastructural study of 10 cases.</article-title>
                <source>Neuropathol Appl Neurobiol.</source>
                <year>1990</year>
                <volume>16</volume>
                <fpage>393</fpage>
                <lpage>400</lpage>
                <pub-id pub-id-type="pmid">2175847</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.corbeilgirard.2005.551">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Corbeil-Girard</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasseville</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavoie</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dicaire</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saint-Denis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Page</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duranceau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Codere</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karpati</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Massie</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langelier</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.</article-title>
                <source>Neurobiol Dis</source>
                <year>2005</year>
                <volume>18</volume>
                <fpage>551</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">15755682</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.davies.2006.23">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarkar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubinsztein</surname>
                    <given-names>DC</given-names>
                  </name>
                </person-group>
                <article-title>Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy.</article-title>
                <source>Hum Mol Genet</source>
                <year>2006</year>
                <volume>15</volume>
                <fpage>23</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">16311254</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.davies.2005.672">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Oroz</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vacher</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Donovan</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubinsztein</surname>
                    <given-names>DC</given-names>
                  </name>
                </person-group>
                <article-title>Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice.</article-title>
                <source>Nat Med</source>
                <year>2005</year>
                <volume>11</volume>
                <fpage>672</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15864313</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.deklerk.2012.9089">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Klerk</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Venema</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anvar</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goeman</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trollet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dickson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>den Dunnen</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Maarel</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raz</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>'t Hoen</surname>
                    <given-names>PA</given-names>
                  </name>
                </person-group>
                <article-title>Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation.</article-title>
                <source>Nucleic Acids Res.</source>
                <year>2012</year>
                <volume>40</volume>
                <fpage>9089</fpage>
                <lpage>101</lpage>
                <pub-id pub-id-type="pmid">22772983</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.dodds.1990.965">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dodds</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Logemann</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>ET</given-names>
                  </name>
                </person-group>
                <article-title>Radiologic assessment of abnormal oral and pharyngeal phases of swallowing.</article-title>
                <source>AJR Am J Roentgenol.</source>
                <year>1990</year>
                <volume>154</volume>
                <fpage>965</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">2108570</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.dubbioso.2012.833">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dubbioso</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moretta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manganelli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fiorillo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iodice</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trojano</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>L.</given-names>
                  </name>
                </person-group>
                <article-title>Executive functions are impaired in heterozygote patients with oculopharyngeal muscular dystrophy.</article-title>
                <source>J Neurol.</source>
                <year>2012</year>
                <volume>259</volume>
                <fpage>833</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21956377</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.duranceau.1997.S85">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Duranceau</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Cricopharyngeal myotomy in the management of neurogenic and muscular dysphagia.</article-title>
                <source>Neuromuscul Disord</source>
                <year>1997</year>
                <volume>7</volume>
                <fpage>S85</fpage>
                <lpage>89</lpage>
                <pub-id pub-id-type="pmid">9392023</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.duranceau.1983.825">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Duranceau</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beauchamp</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jamieson</surname>
                    <given-names>GG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbeau</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Oropharyngeal dysphagia and oculopharyngeal muscular dystrophy.</article-title>
                <source>Surg Clin North Am</source>
                <year>1983</year>
                <volume>63</volume>
                <fpage>825</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">6351296</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.duranceau.1980.33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Duranceau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forand</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fauteux</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <article-title>Surgery in oculopharyngeal muscular dystrophy.</article-title>
                <source>Am J Surg.</source>
                <year>1980</year>
                <volume>139</volume>
                <fpage>33</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">7350844</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.fan.2001.2341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fan</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dion</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laganiere</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death.</article-title>
                <source>Hum Mol Genet</source>
                <year>2001</year>
                <volume>10</volume>
                <fpage>2341</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">11689481</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.fan.2003.244">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fan</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Messaed</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dion</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laganiere</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karpati</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy.</article-title>
                <source>Can J Neurol Sci</source>
                <year>2003</year>
                <volume>30</volume>
                <fpage>244</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">12945950</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.feit.1998.1732">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Feit</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silbergleit</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>LB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutierrez</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitoussi</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reyes</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckmann</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seboun</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Vocal cord and pharyngeal weakness with autosomal dominant distal myopathy: clinical description and gene localization to 5q31.</article-title>
                <source>Am J Hum Genet</source>
                <year>1998</year>
                <volume>63</volume>
                <fpage>1732</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">9837826</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.forood.1995.7">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Forood</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perez-Paya</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houghten</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blondelle</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <article-title>Formation of an extremely stable polyalanine beta-sheet macromolecule.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <year>1995</year>
                <volume>211</volume>
                <fpage>7</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">7779112</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.fukuhara.1980.229">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fukuhara</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsubaki</surname>
                    <given-names>T.</given-names>
                  </name>
                </person-group>
                <article-title>Rimmed vacuoles.</article-title>
                <source>Acta Neuropathol.</source>
                <year>1980</year>
                <volume>51</volume>
                <fpage>229</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">7445977</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.galvao.2001.191">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Galvao</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendes-Soares</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camara</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaco</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carmo-Fonseca</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Triplet repeats, RNA secondary structure and toxic gain-of-function models for pathogenesis.</article-title>
                <source>Brain Res Bull</source>
                <year>2001</year>
                <volume>56</volume>
                <fpage>191</fpage>
                <lpage>201</lpage>
                <pub-id pub-id-type="pmid">11719250</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.gaspar.2000.1957">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gaspar</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jannatipour</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dion</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laganiere</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sequeiros</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation.</article-title>
                <source>Hum Mol Genet</source>
                <year>2000</year>
                <volume>9</volume>
                <fpage>1957</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">10942424</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.gidaro.2013.234">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gidaro</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Negroni</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;ri&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mirabella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lain&#x000e9;</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacau St Guily</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butler-Browne</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mouly</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trollet</surname>
                    <given-names>C.</given-names>
                  </name>
                </person-group>
                <article-title>Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients.</article-title>
                <source>J Neuropathol Exp Neurol.</source>
                <year>2013</year>
                <volume>72</volume>
                <fpage>234</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">23399899</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.goto.1977.600">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goto</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanazawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murai</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuroiwa</surname>
                    <given-names>Y.</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngeal myopathy with distal and cardiomyopathy.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <year>1977</year>
                <volume>40</volume>
                <fpage>600</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">903774</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.grewal.1999.1378">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grewal</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karkera</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grewal</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Detera-Wadleigh</surname>
                    <given-names>SD</given-names>
                  </name>
                </person-group>
                <article-title>Mutation analysis of oculopharyngeal muscular dystrophy in Hispanic American families.</article-title>
                <source>Arch Neurol</source>
                <year>1999</year>
                <volume>56</volume>
                <fpage>1378</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">10555658</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.hill.2004.CD004303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milford</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Treatment for swallowing difficulties (dysphagia) in chronic muscle disease.</article-title>
                <source>Cochrane Database Syst Rev</source>
                <year>2004</year>
                <volume>2</volume>
                <fpage>CD004303</fpage>
                <pub-id pub-id-type="pmid">15106246</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.ishigaki.2001.607">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ishigaki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maquat</surname>
                    <given-names>LE</given-names>
                  </name>
                </person-group>
                <article-title>Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20.</article-title>
                <source>Cell</source>
                <year>2001</year>
                <volume>106</volume>
                <fpage>607</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">11551508</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.jaspar.1977.272">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jaspar</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastiaensen</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>ter Laak</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joosten</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horstink</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stadhouders</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngodistal myopathy with early onset and neurogenic features.</article-title>
                <source>Clin Neurol Neurosurg.</source>
                <year>1977</year>
                <volume>80</volume>
                <fpage>272</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">216518</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.jenal.2012.538">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jenal</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elkon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loayza-Puch</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Haaften</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000fc;hn</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menzies</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oude Vrielink</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bos</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drost</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rooijers</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubinsztein</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agami</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites.</article-title>
                <source>Cell.</source>
                <year>2012</year>
                <volume>149</volume>
                <fpage>538</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">22502866</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.kerwitz.2003.3705">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kerwitz</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuhn</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lilie</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knoth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheuermann</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedrich</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wahle</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Stimulation of poly(A) polymerase through a direct interaction with the nuclear poly(A) binding protein allosterically regulated by RNA.</article-title>
                <source>EMBO J</source>
                <year>2003</year>
                <volume>22</volume>
                <fpage>3705</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">12853485</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.kim.2001.1129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>YJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>YK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukahara</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arahata</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>The product of an oculopharyngeal muscular dystrophy gene, poly(A)-binding protein 2, interacts with SKIP and stimulates muscle-specific gene expression.</article-title>
                <source>Hum Mol Genet</source>
                <year>2001</year>
                <volume>10</volume>
                <fpage>1129</fpage>
                <lpage>39</lpage>
                <pub-id pub-id-type="pmid">11371506</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.kuhn.2003.16916">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuhn</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nemeth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wahle</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>The RNA binding domains of the nuclear poly(A)-binding protein.</article-title>
                <source>J Biol Chem</source>
                <year>2003</year>
                <volume>278</volume>
                <fpage>16916</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">12637556</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.langmore.1991.678">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Langmore</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schatz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olson</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Endoscopic and videofluoroscopic evaluations of swallowing and aspiration.</article-title>
                <source>Ann Otol Rhinol Laryngol.</source>
                <year>1991</year>
                <volume>100</volume>
                <fpage>678</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">1872520</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.leclerc.1993.283">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leclerc</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tom&#x000e9;</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Ubiquitin and beta-amyloid-protein in inclusion body myositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: an immunocytochemical study.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>1993</year>
                <volume>3</volume>
                <fpage>283</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">8268725</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.linoli.1991.325">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Linoli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomelleri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghezzi</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngeal muscular dystrophy. Description of a case with involvement of the central nervous system.</article-title>
                <source>Pathologica.</source>
                <year>1991</year>
                <volume>83</volume>
                <fpage>325</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">1923632</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.manjaly.2012.216">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Manjaly</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaughan-Shaw</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dale</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyler</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corlett</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frost</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Cricopharyngeal dilatation for the long-term treatment of dysphagia in oculopharyngeal muscular dystrophy.</article-title>
                <source>Dysphagia.</source>
                <year>2012</year>
                <volume>27</volume>
                <fpage>216</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">21805106</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.mathieu.1997.S100">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mathieu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lapointe</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brassard</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tremblay</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouchard</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <article-title>A pilot study on upper oesophageal sphincter dilatation for the treatment of dysphagia in patients with oculopharyngeal muscular dystrophy.</article-title>
                <source>Neuromuscul Disord</source>
                <year>1997</year>
                <volume>7</volume>
                <fpage>S100</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9392026</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.mchorney.2002.97">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McHorney</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robbins</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lomax</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenbek</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chignell</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kramer</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bricker</surname>
                    <given-names>DE</given-names>
                  </name>
                </person-group>
                <article-title>The SWAL-QOL and SWAL-CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity.</article-title>
                <source>Dysphagia.</source>
                <year>2002</year>
                <volume>17</volume>
                <fpage>97</fpage>
                <lpage>114</lpage>
                <pub-id pub-id-type="pmid">11956835</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.montgomery.1971.986">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Montgomery</surname>
                    <given-names>WW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngeal muscular dystrophy treated by inferior constrictor myotomy.</article-title>
                <source>Trans Am Acad Ophthalmol Otolaryngol.</source>
                <year>1971</year>
                <volume>75</volume>
                <fpage>986</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">5097831</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.nakamoto.2002.474">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nakamoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawashima</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ihara</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shinde</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kakizuka</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Unequal crossing-over in unique PABP2 mutations in Japanese patients: a possible cause of oculopharyngeal muscular dystrophy.</article-title>
                <source>Arch Neurol</source>
                <year>2002</year>
                <volume>59</volume>
                <fpage>474</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11890856</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.nemeth.1995.4034">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nemeth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krause</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blank</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jenny</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeno</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lustig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wahle</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Isolation of genomic and cDNA clones encoding bovine poly(A) binding protein II.</article-title>
                <source>Nucleic Acids Res</source>
                <year>1995</year>
                <volume>23</volume>
                <fpage>4034</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">7479061</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.perie.1997.S96">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;ri&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laccourreye</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaussade</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacau St Guily</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>Dysphagia in oculopharyngeal muscular dystrophy: a series of 22 French cases.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>1997</year>
                <volume>7</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S96</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9392025</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.perie.1998.1712">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;ri&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laccourreye</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flahault</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hazebroucq</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaussade</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St Guily</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>Role of videoendoscopy in assessment of pharyngeal function in oropharyngeal dysphagia: comparison with videofluoroscopy and manometry.</article-title>
                <source>Laryngoscope.</source>
                <year>1998</year>
                <volume>108</volume>
                <fpage>1712</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9818831</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.perie.2006.770">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;ri&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mamchaoui</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mouly</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blot</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouazza</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thornell</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St Guily</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butler-Browne</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: Therapeutic perspectives of autologous myoblast transplantation.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2006</year>
                <volume>16</volume>
                <fpage>770</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">17005403</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.perie.2014.219">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;ri&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trollet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mouly</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanneaux</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mamchaoui</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouazza</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marolleau</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lafor&#x000ea;t</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapon</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butler-Browne</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larghero</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St Guily</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I/IIa clinical study.</article-title>
                <source>Mol Ther.</source>
                <year>2014</year>
                <volume>22</volume>
                <fpage>219</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">23831596</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.probst.1982.209">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Probst</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tackmann</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoeckli</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jerusalem</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ulrich</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Evidence for a chronic axonal atrophy in oculopharyngeal "muscular dystrophy".</article-title>
                <source>Acta Neuropathol.</source>
                <year>1982</year>
                <volume>57</volume>
                <fpage>209</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">7124348</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.rankin.2000.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rankin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wyttenbach</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubinsztein</surname>
                    <given-names>DC</given-names>
                  </name>
                </person-group>
                <article-title>Intracellular green fluorescent protein-polyalanine aggregates are associated with cell death.</article-title>
                <source>Biochem J</source>
                <year>2000</year>
                <volume>348</volume>
                <fpage>15</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10794708</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.raz.2013.516">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raz</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butler-Browne</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Engelen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brais</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>191st ENMC international workshop: recent advances in oculopharyngeal muscular dystrophy research: from bench to bedside 8-10 June 2012, Naarden, The Netherlands.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2013</year>
                <volume>23</volume>
                <fpage>516</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">23578714</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.restivo.2000.1416">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Restivo</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchese</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Staffieri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Grandis</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Successful botulinum toxin treatment of dysphagia in oculopharyngeal muscular dystrophy.</article-title>
                <source>Gastroenterology</source>
                <year>2000</year>
                <volume>119</volume>
                <fpage>1416</fpage>
                <pub-id pub-id-type="pmid">11185464</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.rodrigue.1997.S82">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rodrigue</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Molgat</surname>
                    <given-names>YM</given-names>
                  </name>
                </person-group>
                <article-title>Surgical correction of blepharoptosis in oculopharyngeal muscular dystrophy.</article-title>
                <source>Neuromuscul Disord</source>
                <year>1997</year>
                <volume>7</volume>
                <fpage>S82</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9392022</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.ruegg.2005.574">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>R&#x000fc;egg</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehky Hagen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hohl</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kappos</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuhr</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plasilov</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinimann</surname>
                    <given-names>K.</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngeal muscular dystrophy - an under-diagnosed disorder?</article-title>
                <source>Swiss Med Wkly.</source>
                <year>2005</year>
                <volume>135</volume>
                <fpage>574</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">16333769</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.salassa.1999.230">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Salassa</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>A functional outcome swallowing scale for staging oropharyngeal dysphagia.</article-title>
                <source>Dig Dis.</source>
                <year>1999</year>
                <volume>17</volume>
                <fpage>230</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10754363</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.satoyoshi.1977.89">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Satoyoshi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinoshita</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngodistal myopathy.</article-title>
                <source>Arch Neurol.</source>
                <year>1977</year>
                <volume>34</volume>
                <fpage>89</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">836191</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.schober.2001.45">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schober</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kress</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grahmann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kellermann</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baum</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;nzel</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>Unusual triplet expansion associated with neurogenic changes in a family with oculopharyngeal muscular dystrophy.</article-title>
                <source>Neuropathology.</source>
                <year>2001</year>
                <volume>21</volume>
                <fpage>45</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">11304042</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.schotland.1964.433">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schotland</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rowland</surname>
                    <given-names>LP</given-names>
                  </name>
                </person-group>
                <article-title>Muscular dystrophy. Features of ocular myopathy, distal myopathy, and myotonic dystrophy.</article-title>
                <source>Arch Neurol.</source>
                <year>1964</year>
                <volume>10</volume>
                <fpage>433</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">14120634</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.scrimgeour.1984.763">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scrimgeour</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mastaglia</surname>
                    <given-names>FL</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngeal and distal myopathy: a case study from Papua New Guinea.</article-title>
                <source>Am J Med Genet.</source>
                <year>1984</year>
                <volume>17</volume>
                <fpage>763</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">6720743</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.stguily.1995.723">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>St Guily</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moine</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;ri&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bokowy</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaussade</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Role of pharyngeal propulsion as an indicator for upper esophageal sphincter myotomy.</article-title>
                <source>Laryngoscope.</source>
                <year>1995</year>
                <volume>105</volume>
                <fpage>723</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">7603277</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.stguily.1994.34">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>St Guily</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;ri&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willig</surname>
                    <given-names>TN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaussade</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelard</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Swallowing disorders in muscular diseases: functional assessment and indications of cricopharyngeal myotomy.</article-title>
                <source>Ear Nose Throat J.</source>
                <year>1994</year>
                <volume>73</volume>
                <fpage>34</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">8162870</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.tome.1997.S63">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tom&#x000e9;</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chateau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Helbling-Leclerc</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy.</article-title>
                <source>Neuromuscul Disord</source>
                <year>1997</year>
                <volume>7</volume>
                <fpage>S63</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9392019</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.tome.1994.1">
              <mixed-citation publication-type="book">Tom&#x000e9; F, Fardeau M. Oculopharyngeal muscular dystrophy. In: <italic toggle="yes">Myology</italic>. New York, NY: McGraw-Hill; 1994:1233-45.</mixed-citation>
            </ref>
            <ref id="opmd.REF.tome.1980.85">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tom&#x000e9;</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Nuclear inclusions in oculopharyngeal dystrophy.</article-title>
                <source>Acta Neuropathol (Berl)</source>
                <year>1980</year>
                <volume>49</volume>
                <fpage>85</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">6243839</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.vandersluijs.2004.1499">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van der Sluijs</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>ter Laak</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheffer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Maarel</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Engelen</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <article-title>Autosomal recessive oculopharyngodistal myopathy: a distinct phenotypical, histological, and genetic entity.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <year>2004</year>
                <volume>75</volume>
                <fpage>1499</fpage>
                <lpage>501</lpage>
                <pub-id pub-id-type="pmid">15377709</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.verheesen.2006.105">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verheesen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Kluijver</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Koningsbruggen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Brij</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Haard</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Ommen</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Maarel</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verrips</surname>
                    <given-names>CT</given-names>
                  </name>
                </person-group>
                <article-title>Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody.</article-title>
                <source>Hum Mol Genet</source>
                <year>2006</year>
                <volume>15</volume>
                <fpage>105</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">16319127</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.victor.1962.1267">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Victor</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayes</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>RD</given-names>
                  </name>
                </person-group>
                <article-title>Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis of the evelids.</article-title>
                <source>N Engl J Med</source>
                <year>1962</year>
                <volume>267</volume>
                <fpage>1267</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">13997067</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.vita.1983.57">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vita</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dattola</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Messina</surname>
                    <given-names>C.</given-names>
                  </name>
                </person-group>
                <article-title>Familial oculopharyngeal muscular dystrophy with distal spread.</article-title>
                <source>J Neurol.</source>
                <year>1983</year>
                <volume>230</volume>
                <fpage>57</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">6194273</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.wahle.1993.2937">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wahle</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lustig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeno</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maurer</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Mammalian poly(A)-binding protein II. Physical properties and binding to polynucleotides.</article-title>
                <source>J Biol Chem</source>
                <year>1993</year>
                <volume>268</volume>
                <fpage>2937</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">8428968</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.wahle.1999.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wahle</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruegsegger</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <article-title>3'-End processing of pre-mRNA in eukaryotes.</article-title>
                <source>FEMS Microbiol Rev</source>
                <year>1999</year>
                <volume>23</volume>
                <fpage>277</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">10371034</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.wang.2005.3673">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mosser</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bag</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells.</article-title>
                <source>Hum Mol Genet</source>
                <year>2005</year>
                <volume>14</volume>
                <fpage>3673</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">16239242</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.young.1980.413">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>ID</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harper</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <article-title>Hereditary distal spinal muscular atrophy with vocal cord paralysis.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <year>1980</year>
                <volume>43</volume>
                <fpage>413</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">7420092</pub-id>
              </element-citation>
            </ref>
            <ref id="opmd.REF.zhao.1999.405">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Formation of mRNA 3' ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis.</article-title>
                <source>Microbiol Mol Biol Rev</source>
                <year>1999</year>
                <volume>63</volume>
                <fpage>405</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">10357856</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="opmd.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="opmd.Author_History">
          <title>Author History</title>
          <p>Bernard Brais, MD, MPhil, PhD; H&#x000f4;pital Notre-Dame-CHUM, Montreal (2001-2014)Gillian Butler-Browne, PhD (2014-present)Teresa Gidaro, MD, PhD (2014-present)Pierre Klein, MSc (2014-present)Jean Lacau St Guily, MD (2014-present)Sophie P&#x000e9;ri&#x000e9;, MD, PhD (2014-present)Guy A Rouleau, MD, PhD; H&#x000f4;pital Notre-Dame-CHUM, Montreal (2001-2014)Capucine Trollet, PhD (2014-present)</p>
        </sec>
        <sec id="opmd.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>20 February 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>22 June 2006 (ca) Comprehensive update posted to live Web site </p>
            </list-item>
            <list-item>
              <p>3 December 2003 (me) Comprehensive update posted to live Web site </p>
            </list-item>
            <list-item>
              <p>8 March 2001 (me) Review posted to live Web site </p>
            </list-item>
            <list-item>
              <p>December 2000 (bb) Original submission </p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="opmd.1.11" sec-type="figs-and-tables">
        <title/>
        <fig id="opmd.F1" position="float" orientation="portrait">
          <label>Figure 1.</label>
          <caption>
            <p>Diagnostic evaluation of dysphagia and ptosis</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="opmdFig1" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
